Company: HCWB
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-058961
Chunk: 27

Company: HCW Biologics Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 27
---
2. Dr. Wong received his Ph.D. degree in Microbiology and Immunology at the University of Massachusetts, Amherst and completed his postdoctoral training at the University of Washington.

We believe that Dr. Wong is qualified to serve as a member of our board of directors due to the perspective and experience he brings as our Founder and Chief Executive Officer, and his extensive experience leading life sciences companies and in the development of immunotherapeutics for cancer and other diseases.

<div align='center'>17</div>

TABLE OF CONTENTS

Family Relationships There is no family relationship between any of the directors or executive officers and any of our other directors or executive officers. Director Compensation Director Compensation Table The following table provides information concerning compensation awarded to, earned by or paid to each person who served as a non-employee member of our board of directors during the fiscal year ended December 31, 2024. Dr. Wong is not included in the table below, as he is employed as our Chief Executive Officer, and receives no compensation for his service as a director. The compensation received by Dr. Wong as an employee is shown in “Executive Compensation-Summary Compensation Table” below.

| Name             |     | Fees Earned or   
 Paid in Cash ($) |        |     | Awards ($)(1)(2) |        |     | Total ($) |        |
| Scott T. Garrett |     |                  | 60,000 |     |                  | 10,570 |     |           | 70,570 |
| Lisa M. Giles    |     |                  | 40,000 |     |                  | 10,570 |     |           | 50,570 |
| Rick S. Greene   |     |                  | 50,000 |     |                  | 10,570 |     |           | 60,570 |
| Gary M. Winer    |     |                  | 40,000 |     |                  | 10,570 |     |           | 50,570 |

(1) The amounts reported in this column represent the aggregate grant date fair value for financial statement reporting purposes of stock options granted 2023 and 2024 as determined in accordance with FASB ASC Topic 718. These amounts reflect our accounting expense for these stock options and do not represent the actual economic value that may be realized by each non-employee director. There can be no assurance that these amounts will ever be realized. For information on the assumptions used in valuing these awards, refer to